An observational study in Prostate Cancer, sponsored by University of California, Davis. Completed. Open to male participants aged 35 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-01-02.
Sponsored by University of California, Davis · Observational
This is a single center pilot study to asses the feasibility of conducting a larger population-based study. It is an investigator-initiated study funded yb the UC Davis Cancer Center's Development Award Program. The hypothesis is that the percent african ancestry in an individual may determine their prognosis if diagnosed with prostate cancer.
6,367 studies on the registry are indexed under Prostatic Neoplasms; 1,397 are open to participants now.
This study's enrollment of 102 is below the median of 200 across 1,179 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →University of California, Davis is the lead sponsor of 798 studies on the registry; 146 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 43 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
African American males between the ages of 35 and 75.
Self-identification as a male with African ancestry Between ages of 35-75
Exclusion Criteria:
No African ancestry Not between ages of 35-75
-
Controls (No prostate cancer)
Cases (Prostate Cancer Diagnosed)
Is there a difference in ancestry percentage between the controls (no cancer) and the cases (prostate cancer)
Time frame: 12 months
No study locations are listed for this record.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Davis